Obesity Specialists Warn Against 'Bootleg' Weight-Loss Drug

Semaglutide, a weight-loss drug developed by Novo Nordisk, is currently in short supply due to high demand, leading some people to seek out "generic" or compounded versions of the drug instead. But obesity specialists warn against using compounded semaglutide since its quality and safety cannot be guaranteed.

According to Ricardo Correa, MD, director of Diversity for Graduate Medical Education and director for the Endocrinology, Diabetes and Metabolism Fellowship at the University of Arizona College of Medicine – Phoenix, compound pharmacies "are probably using the same active pharmacological part (semaglutide), but when you combine things and you add different excipients, the effectiveness — if you don't measure that in a randomized controlled trial — will not be the same."

About the College

Founded in 2007, the University of Arizona College of Medicine – Phoenix inspires and trains exemplary physicians, scientists and leaders to optimize health and health care in Arizona and beyond. By cultivating collaborative research locally and globally, the college accelerates discovery in a number of critical areas — including cancer, stroke, traumatic brain injury and cardiovascular disease. Championed as a student-centric campus, the college has graduated 669 physicians, all of whom received exceptional training from nine clinical partners and more than 2,600 diverse faculty members. As the anchor to the Phoenix Bioscience Core, which is projected to have an economic impact of $3.1 billion by 2025, the college prides itself on engaging with the community, fostering education, inclusion, access and advocacy.